Mauro Montalbano1,2, Cristiana Rastellini1, Joshua T McGuire1, Janika Prajapati1, Ali Shirafkan1, Renza Vento3,4, Luca Cicalese5. 1. Department of Surgery, University of Texas Medical Branch, Galveston, TX, USA. 2. Center of Biomedical Engineering, University of Texas Medical Branch, Galveston, TX, USA. 3. Laboratory of Biochemistry, Department of Biological, Chemical and Pharmaceutical Sciences and Technologies, Polyclinic, University of Palermo, Palermo, Italy. 4. Institute for Cancer Research and Molecular Medicine and Center of Biotechnology, College of Science and Biotechnology, Temple University, Philadelphia, PA, USA. 5. Department of Surgery, University of Texas Medical Branch, Galveston, TX, USA. lucicale@utmb.edu.
Abstract
BACKGROUND: Recently, Glypican-3 (GPC3) has been identified as a potential hepatocellular carcinoma (HCC) diagnostic and/or therapeutic target. GPC3 has been found to be up-regulated in HCC and to be absent in normal and cirrhotic liver. As yet, however, the molecular characteristics of GPC3 and its role in HCC cell physiology and development are still undefined. METHODS: Human hepatocyte cultures were established from 10 HCC patients. Additional liver samples were obtained from 5 patients without cirrhosis and/or HCC. Soft agar colony formation, (co-)immunofluorescence and Western blot assays were used to characterize the hapatocyte cultures. The expression of GPC3 in the hepatocytes was silenced using siRNA, after which, apoptosis, scratch wound migration and transwell invasion assays were performed. RESULTS: We found that in HCC precursor hepatocytes GPC3 is increasingly expressed in different forms and at different locations, i.e., a non-cleaved form (70 kDa) was found to be localized in the cytoplasm while a N-terminal cleaved form (N-GPC3: 40 kDa) was fond to be localized in the cytoplasm and at the extracellular side of hepatocyte membranes. In addition, we found that the non-cleaved form of GPC3 co-localizes with Furin-Convertase in the Golgi apparatus. We also found that, similar to GPC3, Furin-Convertase is expressed in HCC precursor cells, suggesting a role in GPC3 processing. Subsequent siRNA-mediated GPC3 silencing resulted in a temporary inhibition of cell proliferation, migration and ivasion, while inducing apoptosis in transformed hepatocytes. CONCLUSION: Our data reveal new aspects of the role of GPC3 in early hepatocyte transformation. In addition we conclude that GPC3 may serve as a new HCC immune-therapeutic target.
BACKGROUND: Recently, Glypican-3 (GPC3) has been identified as a potential hepatocellular carcinoma (HCC) diagnostic and/or therapeutic target. GPC3 has been found to be up-regulated in HCC and to be absent in normal and cirrhotic liver. As yet, however, the molecular characteristics of GPC3 and its role in HCC cell physiology and development are still undefined. METHODS:Human hepatocyte cultures were established from 10 HCC patients. Additional liver samples were obtained from 5 patients without cirrhosis and/or HCC. Soft agar colony formation, (co-)immunofluorescence and Western blot assays were used to characterize the hapatocyte cultures. The expression of GPC3 in the hepatocytes was silenced using siRNA, after which, apoptosis, scratch wound migration and transwell invasion assays were performed. RESULTS: We found that in HCC precursor hepatocytes GPC3 is increasingly expressed in different forms and at different locations, i.e., a non-cleaved form (70 kDa) was found to be localized in the cytoplasm while a N-terminal cleaved form (N-GPC3: 40 kDa) was fond to be localized in the cytoplasm and at the extracellular side of hepatocyte membranes. In addition, we found that the non-cleaved form of GPC3 co-localizes with Furin-Convertase in the Golgi apparatus. We also found that, similar to GPC3, Furin-Convertase is expressed in HCC precursor cells, suggesting a role in GPC3 processing. Subsequent siRNA-mediated GPC3 silencing resulted in a temporary inhibition of cell proliferation, migration and ivasion, while inducing apoptosis in transformed hepatocytes. CONCLUSION: Our data reveal new aspects of the role of GPC3 in early hepatocyte transformation. In addition we conclude that GPC3 may serve as a new HCC immune-therapeutic target.
Authors: Felix H Shek; Ruibang Luo; Brian Y H Lam; Wing Kin Sung; Tak-Wah Lam; John M Luk; Ming Sum Leung; Kin Tak Chan; Hector K Wang; Chung Man Chan; Ronnie T Poon; Nikki P Lee Journal: Cell Oncol (Dordr) Date: 2017-06-19 Impact factor: 6.730
Authors: M Borzio; S Bruno; M Roncalli; G C Mels; G Ramella; F Borzio; G Leandro; E Servida; M Podda Journal: Gastroenterology Date: 1995-03 Impact factor: 22.682
Authors: Junjie Hu; Li Che; Lei Li; Maria G Pilo; Antonio Cigliano; Silvia Ribback; Xiaolei Li; Gavinella Latte; Marta Mela; Matthias Evert; Frank Dombrowski; Guohua Zheng; Xin Chen; Diego F Calvisi Journal: Sci Rep Date: 2016-02-09 Impact factor: 4.379
Authors: Wei Cheng; Chia-Jen Tseng; Tom T C Lin; I Cheng; Hung-Wei Pan; Hey-Chi Hsu; Yu-May Lee Journal: Carcinogenesis Date: 2008-04-15 Impact factor: 4.944
Authors: Dolores Fernández; Macarena Guereño; María Amparo Lago Huvelle; Magalí Cercato; María Giselle Peters Journal: J Cancer Res Clin Oncol Date: 2018-09-28 Impact factor: 4.553